Status:
TERMINATED
A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
A study to assess the safety and efficacy of MK8245 as monotherapy compared to placebo.
Eligibility Criteria
Inclusion
- Have Type 2 Diabetes Mellitus
- 18 to 65 years of age
Exclusion
- History of Type 1 Diabetes or ketoacidosis
- Have been treated with lipid lowering medications 4 weeks before starting the study
- Have started on a weight loss program and not in the maintenance phase or have started weight loss medication within the last 12 weeks
- Have had surgery in the last 30 days
- History of active liver disease
- History of coronary heart disease or congestive heart failure
- Have had a stroke or transient ischemic neurological disorder in the past 6 months
- Are Human Immunodeficiency Virus (HIV) Positive
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00846391
Start Date
December 1 2008
End Date
August 1 2009
Last Update
February 5 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.